Logo image of JBIO

JADE BIOSCIENCES INC (JBIO) Stock Fundamental Analysis

USA - NASDAQ:JBIO - US0080642061 - Common Stock

11.43 USD
-0.05 (-0.44%)
Last: 11/21/2025, 10:34:21 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to JBIO. JBIO was compared to 533 industry peers in the Biotechnology industry. JBIO has a great financial health rating, but its profitability evaluates not so good. JBIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

JBIO had negative earnings in the past year.
JBIO had a negative operating cash flow in the past year.
In the past 5 years JBIO always reported negative net income.
JBIO had a negative operating cash flow in each of the past 5 years.
JBIO Yearly Net Income VS EBIT VS OCF VS FCFJBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

JBIO has a Return On Assets of -25.15%. This is in the better half of the industry: JBIO outperforms 71.86% of its industry peers.
The Return On Equity of JBIO (-27.94%) is better than 78.99% of its industry peers.
Industry RankSector Rank
ROA -25.15%
ROE -27.94%
ROIC N/A
ROA(3y)-61.34%
ROA(5y)-80.96%
ROE(3y)-66.92%
ROE(5y)-110.13%
ROIC(3y)N/A
ROIC(5y)N/A
JBIO Yearly ROA, ROE, ROICJBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JBIO Yearly Profit, Operating, Gross MarginsJBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

JBIO has more shares outstanding than it did 1 year ago.
JBIO has more shares outstanding than it did 5 years ago.
JBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
JBIO Yearly Shares OutstandingJBIO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
JBIO Yearly Total Debt VS Total AssetsJBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 9.57 indicates that JBIO is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 9.57, JBIO belongs to the best of the industry, outperforming 83.30% of the companies in the same industry.
JBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.57
ROIC/WACCN/A
WACCN/A
JBIO Yearly LT Debt VS Equity VS FCFJBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

JBIO has a Current Ratio of 10.31. This indicates that JBIO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of JBIO (10.31) is better than 82.36% of its industry peers.
A Quick Ratio of 10.31 indicates that JBIO has no problem at all paying its short term obligations.
JBIO has a better Quick ratio (10.31) than 82.36% of its industry peers.
Industry RankSector Rank
Current Ratio 10.31
Quick Ratio 10.31
JBIO Yearly Current Assets VS Current LiabilitesJBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

JBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.35%, which is quite impressive.
EPS 1Y (TTM)89.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

JBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.45% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.05%
EPS Next 2Y40.48%
EPS Next 3Y25.49%
EPS Next 5Y14.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JBIO Yearly EPS VS EstimatesJBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

JBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year JBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JBIO Price Earnings VS Forward Price EarningsJBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JBIO Per share dataJBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

JBIO's earnings are expected to grow with 25.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.48%
EPS Next 3Y25.49%

More info and screens

4

5. Dividend

5.1 Amount

JBIO has a Yearly Dividend Yield of 731.71%, which is a nice return.
JBIO's Dividend Yield is rather good when compared to the industry average which is at 69.85. JBIO pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, JBIO pays a better dividend.
Industry RankSector Rank
Dividend Yield 731.71%

5.2 History

JBIO does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
JBIO Yearly Dividends per shareJBIO Yearly Dividends per shareYearly Dividends per share 2025 20 40 60 80

5.3 Sustainability

DPN/A
EPS Next 2Y40.48%
EPS Next 3Y25.49%
JBIO Yearly Income VS Free CF VS DividendJBIO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 -20M -40M -60M

More info and screens

JADE BIOSCIENCES INC

NASDAQ:JBIO (11/21/2025, 10:34:21 AM)

11.43

-0.05 (-0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners92%
Inst Owner Change0.87%
Ins Owners0.06%
Ins Owner Change0%
Market Cap372.96M
Revenue(TTM)N/A
Net Income(TTM)-56.32M
Analysts90
Price Target19.58 (71.3%)
Short Float %3.4%
Short Ratio6.01
Dividend
Industry RankSector Rank
Dividend Yield 731.71%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date04-29 2025-04-29 (84)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.8%
Min EPS beat(2)-94.83%
Max EPS beat(2)63.24%
EPS beat(4)3
Avg EPS beat(4)-0.09%
Min EPS beat(4)-94.83%
Max EPS beat(4)63.24%
EPS beat(8)3
Avg EPS beat(8)-1.56%
EPS beat(12)4
Avg EPS beat(12)-3%
EPS beat(16)5
Avg EPS beat(16)-6.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.43%
PT rev (3m)15.15%
EPS NQ rev (1m)-10.71%
EPS NQ rev (3m)-73.71%
EPS NY rev (1m)5.96%
EPS NY rev (3m)42.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.85
P/tB 1.85
EV/EBITDA N/A
EPS(TTM)-11.14
EYN/A
EPS(NY)-2.25
Fwd EYN/A
FCF(TTM)-2.03
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0
BVpS6.18
TBVpS6.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.15%
ROE -27.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.34%
ROA(5y)-80.96%
ROE(3y)-66.92%
ROE(5y)-110.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.31
Quick Ratio 10.31
Altman-Z 9.57
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
EPS Next Y96.05%
EPS Next 2Y40.48%
EPS Next 3Y25.49%
EPS Next 5Y14.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y41.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.55%
OCF growth 3YN/A
OCF growth 5YN/A

JADE BIOSCIENCES INC / JBIO FAQ

What is the fundamental rating for JBIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to JBIO.


Can you provide the valuation status for JADE BIOSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to JADE BIOSCIENCES INC (JBIO). This can be considered as Overvalued.


Can you provide the profitability details for JADE BIOSCIENCES INC?

JADE BIOSCIENCES INC (JBIO) has a profitability rating of 1 / 10.


What is the financial health of JADE BIOSCIENCES INC (JBIO) stock?

The financial health rating of JADE BIOSCIENCES INC (JBIO) is 8 / 10.